Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial

Adenoid Cystic Carcinoma Clinical Trial

Official title:

Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04883671
• Other study ID #: 21-171
• Status: Recruiting
• Phase: N/A
• Start date: December 27, 2021
• Est. completion date: June 1, 2030

Study information

• Verified date: October 2023
• Source: Dana-Farber Cancer Institute
• Contact: Jonathan D Schoenfeld, MD, MPH
• Phone: 617-632-5296
• Email: jonathan_schoenfeld[@]dfci.harvard.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to learn whether the early initiation of a specialized and focused type of radiation called stereotactic body radiation therapy (SBRT) will impact the progression of advanced adenoid cystic carcinoma, quality of life, and overall survival.

The name(s) of the study intervention involved in this study is:

• Stereotactic Body Radiation Therapy (SBRT)

Description:

This is a randomized phase II, open-label and non-blinded two-arm study aimed to investigate the potential benefit of treating oligometastatic adenoid cystic carcinoma (ACC) with early initiation of stereotactic body radiotherapy (SBRT). Given the overall uncertainty about the role of local therapy in the treatment of ACC, there is also a prospective observational cohort that will investigate outcomes following local ablative treatments in patients with advanced or metastatic ACC.

This research study is investigating how the specialized and focused stereotactic body radiation therapy (SBRT) impacts disease progression, quality of life, and overall survival in patients with a limited number of metastases (one to five) from their adenoid cystic carcinoma cancer. The use of SBRT to treat all areas of disease after early spread of ACC is investigational. SBRT is a more focused form of radiation compared to the palliative radiation typically received per standard of care treatment. Recent retrospective studies conducted suggest that patients with adenoid cystic carcinoma cancer may benefit from early initiation of a targeted radiation therapy.

The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. After enrollment participants will be randomized into two groups: Standard of Care or Stereotactic body radiotherapy (SBRT). All participants in the study, regardless of treatment regimen, will be followed for up to 10 years.

It is expected that about 66 people will take part in this research study.

Two organizations, Gateway for Cancer Research and the Adenoid Cystic Carcinoma Research Foundation (ACCRF), are supporting this research study by providing funding.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 66
• Est. completion date: June 1, 2030
• Est. primary completion date: June 1, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject must have histologically confirmed adenoid cystic carcinoma (ACC) of any primary site with distant metastases detected clinically or on imaging (biopsy of metastatic disease preferred, but not required)

• Cohort 1

• One to five detectable sites of metastatic disease at any organ or site (including bone and CNS involvement)

• Maximum size of 3 cm for brain lesions.

• Note: Measurable disease is not required

• Note: Patients with isolated intracranial disease for whom SRS would be the preferred standard of care are not eligible.

• Note: Patients may have additional sites of disease for which radiation is not feasible or indicated provided this disease is: 1) Less than 1 cm in maximum diameter on most recent imaging; or 2) Stable over the last 3 months as determined by the investigator

• Cohort 2

• At least 1 site of non-osseous disease

• Cohort 1

• All (up to 5) metastatic foci should be amenable to SBRT as per review by a radiation oncologist based on protocol specified dose / dose constraints (there is no prespecified minimum or maximum size)

• Cohort 2

• At least one metastatic focus amenable to local ablative treatment with any of the following: radiation therapy; radiofrequency, microwave, or cryoablation; bland or chemoembolization

• Cohort 1

• Primary tumor either controlled, or amenable for local treatment with SBRT

• Defined as no evidence of progression at primary or local site of disease (if known) within 6 months prior to enrollment

• Age 18 years or older

• ECOG performance status of 0-2

• Prior systemic therapy is allowed but no therapy (cytotoxic or molecularly targeted agents) 2 weeks prior to the first fraction of radiotherapy, and until after the last fraction of SBRT.

• Cohort 1

• For patients with metastases that have been previously treated (prior resection, radiotherapy, radiofrequency or cryoablation):

• If the previously treated site is controlled based on imaging, the patient is eligible for this trial and does not need further treatment of the controlled site

• If the previously treated site is not controlled based on imaging, the patient is eligible for this trial as long as the site is amenable to SBRT

• Ability to understand and the willingness to sign a written informed consent document.

• Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of (chemo)radiation therapy.

"Women of childbearing potential (WOCBP)" is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL.

• Men who are sexually active with WOCBP must agree to use any contraceptive method with a failure rate of less than 1% per year. Men who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 1 month after treatment. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception. See Appendix B for further guidance on contraception.

Exclusion Criteria:

• Cohort 1

• Subject who has received systemic therapy for treatment of ACC within 2 weeks of enrollment.

• Evidence of need for urgent surgical intervention for metastatic CNS or spine disease.

• Cohort 1

• Alternative locally ablative therapies received (radiofrequency ablation, cryotherapy, or [chemo]embolization) for any metastatic foci planned for SBRT at the time of study enrollment that precludes administration of SBRT.

• Bone metastasis in a femoral bone for which surgical stabilization is recommended.

• Malignant pleural effusion.

• Cohort 1

• Active disease >1 cm that is progressing and not amenable to SBRT.

• Pregnant or lactating women.

• Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

• Has a known additional malignancy that is progressing or requires active treatment. Exceptions: include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer, and low-risk prostate adenocarcinoma being managed with active surveillance. A history of another separate malignancy in remission without evidence of active disease in the last 2 years is permitted.

Related Conditions & MeSH terms

• Adenoid Cystic Carcinoma
• Carcinoma
• Carcinoma, Adenoid Cystic
• Metastatic Adenoid Cystic Carcinoma

Intervention

Other:
• Standard of Care
Participants will be randomly assigned and receive standard of care as determined by their physician and may include: palliative radiation and/or a systemic therapy (like chemotherapy, immunotherapy, or targeted therapies).

Radiation:
• SBRT
SBRT to 1-5 sites of metastatic disease over the course of 1-8 business days to each area of cancer

Locations

Country	Name	City	State
United States	Brigham and Women's Hospital	Boston	Massachusetts
United States	Dana Farber Cancer Institute	Boston	Massachusetts
United States	University of Chicago	Chicago	Illinois
United States	University of California, San Francisco	San Francisco	California

Sponsors (3)

Lead Sponsor	Collaborator
Dana-Farber Cancer Institute	Adenoid Cystic Carcinoma Research Foundation, Gateway for Cancer Research

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival (PFS) (Cohort 1)	Assessed using RECIST v1.1 and Kaplan-Meier	Time from randomization to local, regional, distant progression or death due to any cause, whichever occurs first, assessed up to 5 years
Primary	Local Control Rate (Cohort 2)	Estimating 2-year local control rate following local treatment of ACC lesions. Assessed using RECIST v1.1.	2 years from enrollment
Secondary	Overall Survival (OS)	Assessed using RECIST v1.1 and Kaplan-Meier	Time from randomization to death from any cause or date last known alive, assessed up to 5 years
Secondary	Toxicity Rate	Assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0	Enrollment to end of treatment up to 2 years
Secondary	Quality of Life (QOL) assessments by FACT-G	Descriptive statistics will be performed to characterize QOL data	Baseline and every 3 months for 2 years
Secondary	Local Disease Control Rate	Free of locoregional progression within irradiated oligometastatic sites, assessed using Kaplan-Meier	Time from randomization to free of locoregional progression, assessed up to 5 years
Secondary	Time to next systemic therapy for progression of disease	Assessed using Kaplan-Meier	Time from randomization to initiation of systemic therapy for progression of disease, assessed up to 5 years
Secondary	Time to local therapy for progression of disease	Assessed using Kaplan-Meier	Time from randomization to initiation of local therapy for progression of disease, assessed up to 5 years